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Summary
The transcription factor Pax5 represses lineage-
inappropriate genes and activates B cell-specific
genes in B lymphocytes. By identifying 110 Pax5-
repressed genes, we now demonstrate that Pax5
downregulates diverse biological activities including
receptor signaling, cell adhesion,migration, transcrip-
tional control, and cellular metabolism at B cell com-
mitment. The T lymphoid or myeloid expression of
these genes demonstrates that Pax52/2 pro-B cells
and common lymphoid progenitors display lymphoid
and myeloid promiscuity of gene expression. These
lineage-inappropriate genes require continuous Pax5
activity for their repression, as they are reactivated in
committed pro-B cells and mature B cells following
conditional Pax5 deletion. Pax5-repressed genes are
also reexpressed in plasma cells, which depend for
normal function on Cd28 and Ccr2 reactivation. The
loss of Pax5 during terminal differentiation thus con-
tributes to the plasma cell transcription program.
Finally, ectopic expression of the Pax5-repressed che-
mokine geneCcl3 in B cells results in increased osteo-
clast formation and bone loss, demonstrating that
Pax5-mediated gene repression is essential for normal
homeostasis of hematopoietic development.
Introduction
Hematopoietic development is initiated in the bone mar-
row of adult mice by the decision of HSCs to differentiate
to common myeloid progenitors (CMPs) or lymphoid-
primed multipotent progenitors (LMPPs). Erythroid cell
types arise from CMPs, while myeloid cells can develop
from either CMPs or LMPPs (Adolfsson et al., 2005).
Activation of the lymphoid Rag1 and Rag2 genes in
LMPP cells characterizes the emergence of the earliest
lymphocyte progenitors (ELPs), which differentiate to
common lymphoid progenitors (CLPs) with their charac-
teristic B, T, and NK cell potential (Busslinger, 2004).
The entry of lymphoid progenitors into the B cell path-
way depends on the transcription factors E2A, EBF, and
Pax5 (BSAP). E2A and EBF coordinately activate the
expression of B lymphoid genes in the earliest B cell
progenitors (Busslinger, 2004). Activation of the B cell-
specific transcription program is, however, not sufficient
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in the absence of Pax5. Homozygous Pax5 mutation ar-
rests B cell development at an early pro-B cell stage
(also known as pre-BI or fraction B cells) in the bone
marrow (Nutt et al., 1997). Pax52/2 pro-B cells retain
an extensive self renewal and broad lymphomyeloid
potential characteristic of uncommitted progenitors
(Nutt et al., 1999; Rolink et al., 1999). These Pax52/2
pro-B cells are in vitro clonable lymphoid progenitors
with a latent myeloid potential, as they realize their
lymphoid potential more efficiently than their myeloid
options (Heavey et al., 2003). The restoration of Pax5
expression suppresses the multilineage potential of
Pax52/2 pro-B cells while simultaneously promoting
their development to mature B cells (Nutt et al., 1999).
Conversely, the loss of Pax5 expression by conditional
gene inactivation converts committed pro-B cells with
a restricted B lymphoid potential into lymphoid progen-
itors with a broad developmental potential (Mikkola
et al., 2002). Collectively, these data identified Pax5 as
the critical B-lineage commitment factor.
Uncommitted hematopoietic progenitors including
Pax52/2pro-B cells promiscuously express genes of dif-
ferent lineage programs by a process known as ‘‘lineage
priming’’ (Hu et al., 1997; Nutt et al., 1999; Miyamoto
et al., 2002; Akashi et al., 2003). At B-lineage commit-
ment, Pax5 fulfills a dual role by activating B cell-specific
genes and simultaneously repressing lineage-inappro-
priate genes (Nutt et al., 1999). Pax5 activates target
genes coding for essential components of (pre)BCR sig-
naling such as the signaling chain Iga (mb-1, CD79a), the
stimulatory coreceptor CD19, and the central adaptor
protein BLNK (Nutt et al., 1997; 1998; Schebesta et al.,
2002). Hence, the transactivation function of Pax5 facil-
itates signal transduction from the pre-BCR and BCR,
which constitute important checkpoints in B cell devel-
opment. In contrast, the Pax5-dependent repression of
the Csf1r (M-CSFR) and Notch1 genes renders commit-
ted B cells no longer responsive to the myeloid cytokine
M-CSF or to T cell-inducing Notch1 ligands (Nutt et al.,
1999; Souabni et al., 2002). Based on these two genes,
we hypothesized that the repression function of Pax5
contributes to B-lineage commitment by shutting down
inappropriate signaling systems.
To gain further insight into the repression function of
Pax5, we have now identified 110 Pax5-repressed genes
coding for a plethora of proteins involved in cell-
cell communication, adhesion, migration, nuclear pro-
cesses, and cellular metabolism. The characterization
of these Pax5-repressed genes led to the following con-
clusions. The Pax52/2 pro-B cells and CLPs express not
only lymphoid genes but also a multitude of myeloid
genes, which are repressed by Pax5 at B-lineage com-
mitment. Pax5 is continuously required to repress these
genes, as they are reactivated in pro-B cells and mature
B cells following conditional Pax5 deletion. Pax5-re-
pressed genes are also reactivated in plasma cells, indi-
cating that the physiological loss of Pax5 during terminal
differentiation contributes to the plasma cell transcrip-
tion program. Two of the reactivated genes, Cd28 and
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tion or function. Finally, forced expression of the chemo-
kine gene Ccl3 (MIP-1a) in B cells resulted in increased
osteoclast formation and bone loss, indicating that the
repression function of Pax5 is essential for normal he-
matopoiesis to occur.
Results
Gene Repression by Pax5 in Pro-B Cells
To systematically search for Pax5-repressed genes, we
created a specialized ‘‘pro-B cell’’ microarray by spot-
ting 5000 potentially Pax5-repressed and 5000 poten-
tially Pax5-activated transcripts from cDNA libraries
that were generated by subtracting the transcripts be-
tween Pax5+/+ and Pax52/2 pro-B cells in both direc-
tions. This pro-B cell microarray was hybridized with
Cy3- and Cy5-labeled probes prepared from in vitro-
cultured Pax5+/+ and Pax52/2 pro-B cells, respectively.
Because the wild-type and mutant pro-B cells were
grown under identical conditions as homogeneous cell
populations free of other hematopoietic cell types, all
gene expression changes could be attributed to the
presence or absence of Pax5, which constitutes the
only genetic difference between the two pro-B cell
types. cDNA clones with a Cy5/Cy3 fluorescence ratio
of > 2 (repressed) or < 0.5 (activated) were selected for
further evaluation, demonstrating that Pax5 represses
44% and activates 56% of all differentially expressed
genes (data not shown). Here we describe the character-
ization of the repressed Pax5 target genes.
Sequencing of all cDNA clones with a >2-fold repres-
sion ratio revealed considerable redundancy and thus
high reliability of the hybridization data, as each target
gene was represented on average by w10 different
cDNA clones on the pro-B cell microarray. This analysis
identified 110 distinct Pax5-repressed genes, which
code for six secreted proteins, 24 receptors or cell adhe-
sion molecules, 19 intracellular signal transducers, six
cytoskeleton-associated molecules, 17 metabolic pro-
teins, nine proteases or protease inhibitors, 12 chroma-
tin components or transcription factors, and 17 proteins
of unknown function (see Table S1 in the Supplemental
Data available with this article online). The expression
of 83 genes was validated by RT-PCR analysis of wild-
type and Pax52/2 pro-B cells (Figure 1A), and the mRNA
level of selected genes was additionally quantitated by
RNase protection assay (Figure S1), demonstrating
that the vast majority of the identified genes was re-
pressed >10-fold by Pax5. Five Pax5-repressed genes
code for cell surface proteins, whose expression could
be analyzed at the single-cell level by flow cytometry
(Figure 1B). All Pax52/2 pro-B cells uniformly expressed
the receptors Flt3 and CD28 as well as the cell adhesion
molecules CD11a (Itgal), CD47, and Sca1 (Ly6a) on their
surface in contrast to wild-type pro-B cells. In summary,
we have identified a plethora of Pax5-repressed genes
that define new roles for Pax5 in the downregulation of
diverse cellular functions at B-lineage commitment.
Promiscuous Expression of Lymphoid
and Erythromyeloid Genes in Pax52/2 Pro-B Cells
We next classified the different Pax5-repressed genes
according to their lineage-specific expression pattern.To this end, we hybridized the pro-B cell microarray in-
dividually with Cy3-labeled cDNA probes (red) prepared
from wild-type pro-B cells, thymocytes, macrophages,
and erythroblasts in combination with a Cy5-labeled
Pax52/2 pro-B cell probe (blue; Figure 2). The blue color
in the first two vertical rows confirmed that all identified
genes were transcribed in Pax52/2 pro-B cells but re-
pressed in wild-type pro-B cells. Of these, 25 genes
were preferentially expressed in thymocytes, 25 genes
in macrophages, and four genes in erythroblasts (Fig-
ures 2A–2C). A smaller proportion of the genes showed
a mixed lineage phenotype, with five, four, and ten
genes belonging to the macrophage-erythroblast, mac-
rophage-thymocyte, and mixed lineage clusters, re-
spectively (Figures 2D–2F). A large percentage of Pax5-
repressed genes were either not expressed in any of
the three hematopoietic cell types analyzed (13 genes,
Figure 2G) or were expressed only at a very low level
compared to Pax52/2 pro-B cells (23 genes, Figure 2H).
Some genes in the two latter clusters may, however, be
expressed in hematopoietic cell types other than those
analyzed, which is exemplified by J-chain (Igj) expres-
sion in plasma cells (Rinkenberger et al., 1996). Interest-
ingly, the ‘‘no/low expression’’ clusters also contain two
neuronal genes coding for the glutamate receptor sub-
unit Gria2 and the ectoderm-neural cortex-1 (Enc1) pro-
tein as well as two muscle-specific genes coding for the
transcription factor Mef2c and fast skeletal muscle tro-
ponin I (Tnni2). In conclusion, the Pax52/2 pro-B cells
coexpress lymphoid, myeloid, erythroid, and nonhema-
topoietic genes, which are repressed by Pax5 at B cell
commitment.
Myeloid and Lymphoid Promiscuity of Gene
Expression in CLPs
Recent expression analyses of hematopoietic progeni-
tors led to the conclusion that the myeloid-restricted
CMPs express genes of different myeloid lineages, while
the lymphoid-restricted CLPs express only genes of
lymphoid lineages (Miyamoto et al., 2002; Akashi et al.,
2003). Since the Pax52/2 pro-B cells as lymphoid pro-
genitors are closely related to CLPs (Heavey et al.,
2003; Balciunaite et al., 2005), we were surprised to
see that Pax52/2 pro-B cells express as many myeloid
as lymphoid genes. To rule out any in vitro culture arti-
fact, we analyzed the expression of selected myeloid
and T lymphoid genes in MPPs (LSK), CMPs, CLPs,
pro-B, pre-B, immature B cells, thymocytes, and mye-
loid Gr1+Mac1+ cells, which were FACS sorted as highly
purified cell populations (Figure S2). RT-PCR analysis of
the Pax5-repressed genes in these sorted cell types led
to three major conclusions (Figure 3). First, these genes
were repressed in vivo from the committed pro-B cell to
the immature B cell stage consistent with their identifi-
cation as Pax5-repressed genes. Second, all genes an-
alyzed were expressed in CLPs as predicted by their ex-
pression in Pax52/2 pro-B cells. Third, the myeloid but
not lymphoid genes were also expressed in the CMPs
and MPPs. The myeloid Pax5-repressed genes can fur-
thermore be grouped into two classes. Seven genes
(Emb, Flt3, Ramp1, Lmo2, AI789751, Wbscr5, and
Ccl3) were expressed at similar levels in CLPs and mye-
loid Gr1+Mac1+ cells, demonstrating that their expres-
sion in the CLPs cannot be caused by myeloid cell
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(A) RT-PCR analysis. Differential expression of the indicated genes was validated by RT-PCR analysis using 10-fold serial dilutions of cDNA pre-
pared from in vitro cultured wild-type (+/+) and Pax5 mutant (2/2) pro-B cells. Hypoxanthine phosphoribosyltransferase (Hprt) expression was
used to normalize the cDNA input and fibroblast-specific fibronectin 1 (Fn1) transcripts to control for the absence of stromal ST2 cell contam-
ination (controls). Representative results of one of two pro-B cell pairs analyzed are shown. The annotation and alternative names of the Pax5-
repressed genes is provided in Table S1.
(B) Flow cytometric analysis of the indicated cell surface proteins on cultured wild-type (dashed line) and Pax52/2 (black line) pro-B cells.contamination. In contrast, four genes (Ccl9, Fc3r1g,
Ccr2, and Lilrb4) were expressed at about a 50-fold
higher level in myeloid Gr1+Mac1+ cells compared to
CLPs. It is thus possible, although not very likely due
to the double sorting procedure used, that the tran-
scripts of these genes in the purified CLP population
originate from a minor contamination of myeloid cells.
Moreover, it is important to note that all four genes
were also expressed in the contamination-free, in vitro-
cultured Pax52/2 pro-B cells (Figure 1). We conclude,
therefore, that the CLPs, like the Pax52/2 pro-B cells,
exhibit not only lymphoid but also myeloid promiscuity
of gene expression.
Reversibility of Pax5-Mediated Gene Repression
in Pro-B Cells
We next investigated whether the Pax5-repressed
genes are reactivated upon conditional Pax5 loss inCreED-30 Pax5F/F pro-B cells expressing a Cre-ER fu-
sion protein (Mikkola et al., 2002). In this induction sys-
tem, the floxed (F) exon 2 of Pax5 is efficiently deleted
upon Cre-ER activation, leading to a shift from func-
tional Pax5 mRNA to the truncated transcript within 1
day of 4-hydroxytamoxifen (OHT) treatment (Figure 4A;
controls). The Pax5 protein was reduced to low levels
at day 4 (Mikkola et al., 2002), when the expression of
the activated Pax5 target geneCd19 started to be down-
regulated (Figure 4A). In parallel, the Pax5-repressed
genes were reactivated in the same pro-B cells, thus
providing unequivocal independent confirmation that
the identified genes are negatively regulated by Pax5
(Figure 4A). Surprisingly, many genes were reactivated
with similar kinetics as the J-chain (Igj) gene (Figure 4A),
which is known to be a direct target of Pax5 repression
(Rinkenberger et al., 1996). Together, these data indi-
cate a continuous requirement of Pax5 for gene repres-
sion in committed pro-B cells.
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Genes in Different Hematopoietic Lineages
The mouse pro-B cell microarray was hybrid-
ized with a Cy5-labeled cDNA probe pre-
pared from cultured Pax5 mutant (2/2) pro-
B cells (blue color) in combination with a
Cy3-labeled probe prepared from the follow-
ing lineage-specific cells (Lin+; red color): two
different wild-type (+/+) pro-B cell lines, bone
marrow-derived macrophages (M), Thy1.2+
thymocytes (T), or bone marrow-derived
erythroblasts (E). The hybridization data are
depicted as expression ratios of the indi-
vidual genes in the Lin+ cells relative to
Pax52/2 pro-B cells according to the color
scale shown.Reactivation of Repressed Genes in Mature B Cells
upon Pax5 Loss
To study whether Pax5 is still required for gene repres-
sion in mature B cells, we took advantage of the Cd19-
cre line, which efficiently deletes the floxed Pax5 allele
only in mature B cells leading to upregulation of CD25
(Horcher et al., 2001). We therefore sorted mature
Pax5-deficient (Pax5D/2) B cells as CD25+IgM+ cells from
the lymph nodes of Cd19-cre Pax5F/2 mice after deple-
tion of non-B cells, whereas control Pax5D/+ B cells were
isolated as CD252IgM+ cells from Cd19-cre Pax5F/+
mice (Figure S3). RT-PCR analysis confirmed deletion
of the floxed Pax5 allele in all sorted Pax5D/2 B cells,
leading to decreased expression of the activated Pax5
target gene Cd19 (Figure 4B; Horcher et al., 2001). Im-
portantly, the loss of Pax5 led to efficient reactivation
of the repressed genes Ccl3, Ccr5, Flt3, Emb, Fc3r1g,
Cd28, and J-chain (Igj) in mature Pax5D/2 B cells, while
the same genes were repressed in control Pax5D/+ B
cells (Figure 4B). Moreover, these seven genes were ex-
pressed in Pax5D/2 B cells at a comparable or even
higher level compared toPax52/2 pro-B cells (Figure 4B)
similar to the Csf1r (M-CSFR) gene (Tagoh et al., 2004).
Hence, the repression of these lineage-inappropriate
genes requires the continuous presence of Pax5 from
the pro-B to the mature B cell stage. Interestingly, the
Pax5 loss in mature B cells strongly activated the
Prdm1 gene coding for the plasma cell transcription fac-
tor Blimp1 (Shapiro-Shelef et al., 2003). In contrast,Pax5
inactivation in either mature B cells (Figure 4B) or pro-Bcells (Figure 1) did not affect expression of the transcrip-
tion factor genes Bcl6 and Xbp1, which are essential for
germinal center B cell and plasma cell development,
respectively (Dent et al., 1997; Reimold et al., 2001).
This genetic evidence thus suggests a role for Pax5 in
Prdm1 repression, while the regulation of Bcl6 and
Xbp1 does not depend on Pax5 function.
Expression of Pax5-Repressed Genes
in Plasma Cells
Under physiological conditions, Pax5 expression is
downregulated during antigen-driven development of
mature B cells into immunoglobulin-secreting plasma
cells (Busslinger, 2004). To investigate whether the
Pax5-repressed genes are reactivated during terminal
plasma cell differentiation, we stimulated B220+CD19+
B cells from the spleen of Vav-bcl2 transgenic mice
with the polyclonal activator LPS for up to 9 days (Fig-
ure 5A). LPS stimulation led to the downregulation of
Pax5 expression within 3 days. Starting at day 3, the
plasma cell-specific genes Cd138 (Syndecan-1) and
Xbp1 were activated together with a multitude of Pax5-
repressed genes including Prdm1 (Blimp1) (Figure 5A;
Figure S4). Hence, the physiological loss of Pax5 during
terminal differentiation leads to reactivation of lineage-
promiscuous genes in plasma cells.
We next isolated in vivo plasma cells from heterozy-
gous IgHGFP/+mice, which express the green fluorescent
protein (GFP) gene under the control of the endogenous
immunoglobulin heavy-chain (IgH) locus (Figure S5A).
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Myeloid and T Lymphoid Genes in CLPs
The expression of the indicated Pax5-re-
pressed genes was analyzed by RT-PCR in
the various hematopoietic cell types shown.
The cDNA input of each sorted cell popula-
tion was normalized for equal expression of
the small ribosomal protein gene S16 prior
to PCR analysis of 5-fold serial dilutions of
the cDNA. The different cell types were iso-
lated by FACS sorting (Figure S2) as de-
scribed in Experimental Procedures.IgHGFP/+ mice were immunized by intraperitoneal injec-
tion of sheep red blood cells, and plasma cells were
sorted 14 days later as a homogeneous population of
Lin2GFPhiCD138hi cells from the bone marrow and
spleen (Figure 5C; Figures S5B and S5C). These plasma
cells expressed Pax5 at an w50-fold lower level com-
pared to splenic B cells (Figure 5B). Interestingly, the
Pax5-repressed genes, which were activated during
LPS-induced differentiation of B cells, were also ex-
pressed in the sorted plasma cells of both origins (Fig-
ure 5B). Transcripts of the Prdm1 (Blimp1), J-chain (Igj),
and CD28 genes were even more abundant in plasma
cells compared toPax52/2 pro-B cells, whereas Emb, It-
gal, Ly6a,Notch1, Fc3r1g, Serpinb6b, andMyl4were ex-
pressed at similar levels in both cell types. Flow cytomet-
ric analysis furthermore revealed high expression of
CD28, Sca1 (Ly6a), and CD11a (Itgal) on bone marrow
plasma cells (GFPhiCD138hi, back line) compared to
splenic B cells (dashed line) in IgHGFP/+ mice (Figure 5C).
We conclude, therefore, that the downregulation ofPax5
expression during terminal differentiation contributes to
the plasma cell transcription program by facilitating the
reactivation of previously repressed genes.
Reactivation of Cd28 and Ccr2 Is Essential
for Normal Plasma Cell Function
We next investigated whether reactivation of the Pax5-
repressed genes Cd28, Ccr2, and Ccl3 is important forplasma cell function. The costimulatory receptor CD28
of T cells enhances signaling through the T cell receptor
by binding to the ligands CD80 (B7.1) and CD86 (B7.2) on
activated B cells, which is essential for germinal center
formation in lymphoid organs (Shahinian et al., 1993;
Ferguson et al., 1996). The chemokine receptor CCR2
(binding the ligand CCL2 [MCP-1]) and the chemokine
CCL3 (MIP-1a; binding to the receptor CCR5) both me-
diate macrophage chemotaxis and regulate effector T
cell function (Kuziel et al., 1997; Trifilo et al., 2003). As
these three genes are expressed in multiple hematopoi-
etic cell types including T cells, we used competitive
bone marrow reconstitution to generate mice that spe-
cifically lack one of the three genes only within the
B-lymphoid lineage. To this end, we transplanted le-
thally irradiated Rag22/2 mice with a 1:1 mixture of
bone marrow from Vav-cre Pax5F/F mice and from
Cd282/2,Ccr22/2,Ccl32/2or wild-type mice (Figure 6A).
As Vav-cre Pax5F/F mice lack B lymphocytes due to he-
matopoietic-specific deletion of the B lymphoid gene
Pax5 (Figure 6B; Figure S7C), all B cells and plasma cells
in the reconstitutedRag22/2mice can develop only from
the transplantedCd282/2,Ccr22/2,Ccl32/2 or wild-type
HSCs. In contrast, all T cells in theCd282/2 reconstituted
mice expressed the costimulatory receptor CD28, which
thus provided a selective advantage for the devel-
opment of T cells derived from the Vav-cre Pax5F/F
HSCs (Figure 6C). Six weeks after transplantation, the
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(A) Reactivation of repressed genes upon Pax5 loss in committed pro-B cells. Transcripts of the indicated genes were analyzed by RT-PCR at
different days after 4-hydroxytamoxifen (OHT) treatment of pro-B cells from CreED-30 Pax5F/F mice. PCR products corresponding to the full-
length (FL) Pax5 mRNA or truncated Pax5 transcript lacking exon 2 (DE2) are indicated.
(B) Reversibility of Pax5-mediated gene repression in mature B cells. Mature control or Pax5-deficient B cells were isolated free of contaminating
non-B cells from the lymph nodes of Cd19-cre Pax5F/+ mice (abbreviated as Pax5D/+) or Cd19-cre Pax5F/2 (Pax5D/2) mice, respectively (Fig-
ure S3). Both cell types were analyzed for expression of the indicated transcripts by RT-PCR of 5-fold serial cDNA dilutions.reconstituted mice were subcutaneously injected with
the T cell-dependent antigen NIP-Ovalbumin in com-
plete Freund’s adjuvant, and the spleen and serum
were analyzed 14 days later (Figure 6A). Germinal center
B cells (PNA+B220+) were detected by flow cytometry
(Figure 6D), and immunohistochemistry identified abun-
dant germinal centers in the spleen of the reconstituted
mice (Figure 6E). ELISA measurements revealed compa-
rable levels of total IgG1 in the serum of the different re-
constituted mice (Figure 7F). Moreover, the titers of NIP-
specific IgG1 were also similar in the mice reconstituted
with wild-type or Ccl32/2 bone marrow (Figure 7F), indi-
cating that CCL3 is not essential for plasma cell function
despite expression of its receptor CCR5 (Figure 5B). In
contrast, mice reconstituted with Cd282/2 or Ccr22/2bone marrow had on average a 10-fold lower level of
NIP-specific IgG1. These data therefore identified a
B-lineage-intrinsic role for CD28 and CCR2 in controlling
the differentiation or function of plasma cells beyond
germinal center formation.
Ccl3 Expression in B Cells Causes Increased
Osteoclast Formation and Bone Loss
The Pax5-repressed chemokine gene Ccl3 (MIP-1a) and
the Tnfsf11 gene coding for the osteoprotegerin ligand
(OPGL, RANKL) are both known to promote osteoclast
formation and thus bone destruction (Kong et al.,
1999; Oyajobi et al., 2003). The Pax5-dependent repres-
sion of Ccl3 (MIP-1a) and/or Tnfsf11 (OPGL) transcrip-
tion in B cells may therefore be essential to prevent
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275Figure 5. Expression of Pax5-Repressed
Genes in Plasma Cells
(A) Reactivation of Pax5-repressed genes
during LPS-induced plasma cell differentia-
tion. The indicated transcripts were analyzed
by RT-PCR at different days after in vitro LPS
treatment of sorted Lin2B220+CD19+ spleno-
cytes from Vav-bcl2 transgenic mice.
(B) Expression of Pax5-repressed genes in
plasma cells. IgHGFP/+ mice (Figure S5A)
were immunized with sheep red blood cells.
After 14 days, plasma cells were sorted from
the bone marrow and spleen as Lin2GFPhi
CD138hi cells (Figures S5B and S5C) followed
by RT-PCR analysis of 5-fold serial cDNA
dilutions. Splenic B cells were sorted as
Lin2B220+CD19+ cells.
(C) Cell surface expression. The expression
of CD28, Sca1, and CD11a was analyzed by
flow cytometry on GFPhiCD138hi plasma cells
(black lines) from the bone marrow of immu-
nized IgHGFP/+ mice and compared to the cor-
responding expression of splenic B220+
CD19+ B cells (dashed lines).excessive osteoclast formation leading to imbalanced
hematopoiesis. To test this hypothesis, we used a trans-
genic strategy to maintain Ccl3 expression in all B lym-
phocytes, where the endogenous Ccl3 gene is normally
repressed by Pax5 (Figures 1, 3, and 4). To this end, we
inserted a mouse Ccl3 minigene together with a human
(h) Cd2 indicator gene into the Cd19 locus (Figure 7A),
which is exclusively expressed in B lymphocytes under
the stringent control of Pax5 (Nutt et al., 1998). The
Cd19Ccl3 BAC as well as a control Cd19hCd2 BAC, con-
taining only the hCd2 gene, were injected into oocyte
pronuclei to generate transgenic mice. At an expected
frequency, we obtained Cd19hCd2 transgenic mice that
expressed the hCd2 gene in all B lymphocytes but not
in myeloid, erythroid, or T lymphoid cells, thus validating
our transgenic strategy (Figure S6). Despite repeated
attempts, we obtained, however, only one weakly ex-
pressing Cd19Ccl3 transgenic line, suggesting that con-
stitutive Ccl3 expression in B cells may interfere with
the survival to adulthood (data not shown). Hence, we
next analyzed transgenic founder (G0) embryos at day18.5 of gestation. Two embryos expressed the Cd19Ccl3
transgene in all B lymphocytes of the fetal liver (Fig-
ure 7B) at an average mRNA level that was comparable
to that of Pax52/2 bone marrow pro-B cells (Figure 7C).
Histological analysis uncovered a loss of trabecular
bone in the long bones of the Cd19Ccl3 transgenic em-
bryos compared to control littermates, which was best
visualized by van Kossa staining of the mineralized
bone areas (Figure 7D). The observed bone loss was ac-
companied by a corresponding increase in tartrate-re-
sistant acid phosphatase (TRAP)-positive osteoclasts
in Cd19Ccl3 transgenic relative to wild-type embryos
(Figure 7D). Increased osteoclast formation was further
demonstrated by abundant expression of the osteo-
clast-specific cathepsin K (Ctsk) gene (Rantakokko
et al., 1996) in Cd19Ccl3 transgenic bones in contrast to
wild-type bones. Hence, normal osteoclast develop-
ment and thus homeostasis of the hematopoietic sys-
tem depends on the repression of Ccl3 in B cells, which
identifies a critical role for the repression function of
Pax5.
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Repressed Genes Is Important for Plasma
Cell Function
(A) Schematic diagram describing the bone
marrow reconstitution and immunization of
Rag22/2 mice. The T cell-dependent antigen
NIP-Ovalbumin (NIP-Ova) was subcutane-
ously injected in complete Freund’s adjuvant.
The bone marrow (BM) of Vav-cre Pax5F/F
mice is referred to as Pax5D/D BM.
(B) Absence of B cells (CD19+B220+) in the
bone marrow of Vav-cre Pax5F/F mice in con-
trast to Cd282/2 mice.
(C) Uniform expression of CD28 on thymo-
cytes of Rag22/2 mice after competitive re-
constitution with Cd282/2 and Pax5D/D bone
marrow (Cd282/2 rec; back surface).
(D) Presence of germinal center B cells
(PNA+B220+) in the spleen of immunized
mice, which were reconstituted (rec) with
bone marrow of the indicated genotypes
and Pax5D/D bone marrow.
(E) Formation of normal germinal centers in
the spleen of immunized reconstituted mice.
Cryosections of the spleen were stained with
FITC-anti-IgD antibody (blue) and biotiny-
lated peanut hemagglutinin (PNA, brown) fol-
lowed by detection with an alkaline phospha-
tase-coupled anti-FITC antibody (visualized
with Fast Blue) and horseradish peroxidase-
conjugatedstreptavidin (visualizedwithDAB),
respectively.
(F) Impaired immune response in mice with
Cd282/2 andCcr22/2B-lineage cells. The se-
rum titers of total IgG1 and NIP-specific IgG1
were determined by ELISA 14 days after im-
munizing reconstituted mice of the indicated
genotypes.Pax5 mutant mice were recently shown to exhibit
early-onset osteopenia due to increased osteoclast de-
velopment (Horowitz et al., 2004). We could confirma massive loss of trabecular bone in the long bones of
12-day-old Pax52/2 mice (Figure S7A). Surprisingly,
however, the formation of trabecular bone appeared to
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(A) Cd19Ccl3 transgene. The mouse Ccl3 cDNA, which was linked via IRES to a human (h) intracellularly truncated (t) Cd2 gene, was inserted into
exon 1 of a Cd19 BAC. pA, polyadenylation site.
(B) B cell-specific expression of the Cd19Ccl3 transgene. Fetal liver cells were isolated from a transgenic (tg) founder (G0) embryo (black line) and
wild-type (wt) littermate (dashed line) at day 18.5 and stained with lineage-specific antibodies. The expression of hCD2 is displayed for B lym-
phoid (CD19+), myeloid (Mac1+Gr1+), and erythroid (Ter119+) cells.
(C) Ccl3 mRNA levels. Ccl3 expression was compared by RT-PCR in sorted CD19+ fetal liver (FL) cells and cultured pro-B cells of the indicated
genotypes.
(D) Bone phenotype of Cd19Ccl3 transgenic embryos. Adjacent sections through the hindlimb (tibia) of transgenic and wild-type E18.5 embryos
were analyzed by hematoxylin and eosin (HE), van Kossa, and TRAP staining and by in situ hybridization analysis of cathepsin K (Ctsk) expres-
sion. Van Kossa staining visualizes the mineralized trabecular and cortical bones in black color. Arrowheads point to TRAP-positive (red) and
cathepsin K-expressing (blue) osteoclasts. Dashed lines indicate the contours of the bone. The same bone phenotype was observed with a sec-
ond independent Cd19Ccl3 transgenic embryo.be normal in Vav-cre Pax5F/F mice, indicating that hema-
topoietic-specific deletion of Pax5 by Vav-cre does not
lead to increased osteoclast development (Figure S7B).
The difference in bone phenotype between the Vav-cre
Pax5F/F and Cd19Ccl3 mice is likely explained by the
low number of Pax5-deficient pro-B cells in the Vav-
cre Pax5F/F bone marrow, which produce little CCL3
compared to all the abundant B lymphocytes of the
Cd19Ccl3 mouse (Figure S7C). Hence, the severe osteo-
penia observed in Pax52/2 mice is not the result of Pax5
deficiency in the hematopoietic system but instead must
be caused by the lack of another, nonhematopoietic
function of Pax5.
Discussion
B cell commitment critically depends on the transcrip-
tion factor Pax5 (BSAP), which activates B cell-specificgenes and simultaneously represses lineage-inappropri-
ate genes at the onset of B cell development (Busslinger,
2004). Here we have identified 110 Pax5-repressed
genes by cDNA microarray analysis, which provided
important insight into the repression function of Pax5
during B lymphopoiesis as discussed below.
Changes in Cell Signaling, Adhesion, and Migration
at B Cell Commitment
The Pax5-repressed genes fulfill diverse functions in dif-
ferent hematopoietic cell types, indicating that Pax5
downregulates a broad range of biological activities
including cell-cell communication, cell adhesion, migra-
tion, nuclear processes, and cellular metabolism at B cell
commitment. A major class of repressed genes codes for
secreted proteins, transmembrane receptors, and intra-
cellular signal transducers. The cytokine OPGL (RANKL;
encoded by Tnfsf11) controls osteoclast development
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278and lymphopoiesis (Kong et al., 1999), while the insulin-
like growth factor 2 (Igf2) regulates the proliferation
of HSCs and erythromyeloid progenitors (Zhang and
Lodish, 2004). Several Pax5-repressed genes code for
cell surface receptors such as the tyrosine kinase recep-
tor Flt3 controlling the proliferation and differentiation of
multipotent progenitors (MPPs) and CLPs (Stirewalt and
Radich, 2003); the GPI-anchored Ly6a (Sca1) protein
regulating HSC self-renewal, myeloid progenitor devel-
opment, and T cell proliferation (Ito et al., 2003); the co-
stimulatory receptor CD28 of T cells (Shahinian et al.,
1993); the signal-transducing common g chain (FcRg;
encoded by Fc3r1g) of activating Fc receptors on mye-
loid cells (Takai, 2002); the subunit Ramp1 of the calcito-
nin gene-related peptide (CGRP) receptor implicated in
myeloid progenitor development (Broome et al., 2000);
and the inhibitory receptor Gp49b (encoded by Lilrb4)
of NK and mast cells (Feldweg et al., 2003). Intracellular
signaling molecules encoded by Pax5-repressed genes
include the tyrosine kinase Lck (Molina et al., 1992), the
catalytic subunit Aa (encoded by Ppp3ca) of the calci-
neurin phosphatase (Zhang et al., 1996), and the adaptor
molecule Grap2 (Mona, Gads; Yoder et al., 2001), which
are all involved in transducing signals from the (pre)TCR
in T cells. The transmembrane adaptor protein NTAL/
LAB (encoded by Wbscr5) mediates signaling of the
Fcg and Fc3 receptors in myeloid cells (Brdicka et al.,
2002), while the b spectrin Spnb2 (ELF) functions as an
adaptor in TGFb signaling (Tang et al., 2003). In sum-
mary, the Pax5-dependent repression of these signaling
molecules unequivocally demonstrates that Pax5 down-
regulates multiple signal transduction pathways in addi-
tion to the previously identified M-CSFR (Csf1R) and
Notch signaling systems (Nutt et al., 1999; Souabni
et al., 2002) and thus renders committed B lymphocytes
unresponsive to lineage-inappropriate signals.
Lymphoid progenitors undergo a dramatic change in
cell migration and adhesion at B-lineage commitment.
The committed pro-B cells (Flt32B220+CD19+c-Kit+) ad-
here to a specialized bone marrow niche consisting of
IL-7-expressing CXCL122 stromal cells (Tokoyoda
et al., 2004). In contrast, uncommitted pre-pro-B cells,
which have the same cell surface phenotype (Flt3+
B220+CD192) and developmental potential as Pax52/2
pro-B cells (Balciunaite et al., 2005), are located in a sep-
arate bone marrow environment composed of VCAM-1+
IL-72 stromal cells expressing the chemokine CXCL12
(SDF1; Tokoyoda et al., 2004). Interestingly, CXCL12
induces an efficient chemotactic response in uncommit-
ted pre-pro-B cells (Tokoyoda et al., 2004) and Pax52/2
pro-B cells (Figure S8B), indicating that this chemokine
retains uncommitted lymphoid progenitors in the
CXCL12+IL-72 stromal cell niche. The CXCR4 receptor
for CXCL12 is, however, equally expressed in lymphoid
progenitors and committed pro-B cells (Tokoyoda et al.,
2004; Figure S8A), suggesting that CXCL12-induced
changes in integrin signaling may account for the altered
migration and adhesion behavior of lymphocytes at B
cell commitment. The chemokine CXCL12 activates,
by inside-out signaling, the high-affinity binding state
of the integrin adhesion receptors VLA-4 (a4b1 binding
to VCAM-1) and LFA-1 (aLb2 binding to ICAM-1; Con-
stantin et al., 2000), which are both coexpressed on
uncommitted pre-pro-B and Pax52/2 pro-B cells (To-koyoda et al., 2004; Figure S8A). In contrast, LFA-1
expression is selectively downregulated on committed
pro-B cells due to Pax5-dependent repression of the
subunit aL integrin (Itgal, CD11a; Figure 1). Pax5-
repressed genes also code for the transmembrane pro-
tein CD47 (Brown and Frazier, 2001) and tetraspanin
Tm4sf2 (Zemni et al., 2000), which regulate adhesion-
dependent signaling by interacting with integrin recep-
tors, while Embigin (Emb) promotes cell adhesion in
a yet unknown manner (Huang et al., 1993). In addition
to the chemokine receptors CCR2 and CCR5, other
Pax5-repressed regulators of cell migration and adhe-
sion include the signal-transducing molecule Lsp1 (Har-
rison et al., 2004), the Rho guanine nucleotide exchange
factor Vav3 (Gakidis et al., 2004), and the Rho GTPase-
activating protein Daam1 (Habas et al., 2001), which
are involved in controlling the actin cytoskeleton. In
summary, Pax5 alters the adhesion and migration prop-
erties of lymphoid progenitors by downregulating multi-
ple components of chemokine and intergrin signaling
pathways.
Promiscuous Expression of Myeloid Genes
in Lymphoid Progenitors
The lineage priming hypothesis predicts that some tran-
scriptional activation of lineage-specific differentiation
programs precedes commitment to any particular he-
matopoietic lineage (Hu et al., 1997). Two previous re-
ports demonstrated that MPPs (LSKs) coexpress mye-
loid and lymphoid genes, whereas differentiation to
CMPs correlates with the downregulation of lymphoid
genes and differentiation to CLPs with the repression
of erythromyeloid genes (Miyamoto et al., 2002; Akashi
et al., 2003). In view of these data, we were surprised
about the expression of a multitude of myeloid genes in
Pax52/2 pro-B cells, which we previously characterized
as lymphoid progenitors (Heavey et al., 2003). Moreover,
our analysis detected the expression of both lymphoid
and myeloid Pax5-repressed genes in CLPs, while
MPPs and CMPs predominantly express myeloid but
not lymphoid Pax5-regulated genes. These data agree
with the conclusion of Miyamoto et al. (2002) that the
promiscuous transcription of myeloid genes is initiated
in HSCs and MPPs and that the expression of lymphoid
genes is only activated following lymphoid commitment
of MPPs. However, our results also demonstrate that
CLPs exhibit not only lymphoid but also myeloid pro-
miscuity that is repressed only at B cell commitment
by Pax5. This finding is likely to account for the latent
myeloid potential of CLPs (Kondo et al., 2000) and un-
committed pre-pro-B cells (Balciunaite et al., 2005).
Pax52/2 progenitors express, however, very few ery-
throid genes, consistent with the finding that HSCs
give rise to erythroid-megakaryocytic progenitors be-
fore commitment to the myeloid and lymphoid lineages
(Adolfsson et al., 2005).
Reactivation of Pax5-Repressed Genes
in Plasma Cells
Based on genetic studies of fly and mouse develop-
ment, it is thought that transcription factors initiate cell
fate decision by altering gene expression patterns,
while the transcriptional state of committed cells is
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279subsequently maintained by epigenetic factors encoded
by the Polycomb and Trithorax group genes (Ringrose
and Paro, 2004). In particular, the chromatin-modifying
Polycomb group protein complexes are responsible
for the epigenetic maintenance of the repressed state
(Ringrose and Paro, 2004). It was therefore surprising
to see that the B-lineage commitment factor Pax5 is con-
tinually required to repress lineage-inappropriate genes
throughout B cell development, as the mere loss of
Pax5 leads to reactivation of Pax5-repressed genes
not only in pro-B cells but also in mature B cells. The
observed transcriptional plasticity of B cells could also
explain why the suppression of Pax5 activity by C/EBP
transcription factors allows B cells to transdifferentiate
into macrophages under myeloid cytokine conditions
(Xie et al., 2004). Physiological stimulation by foreign an-
tigen induces, however, mature B cells to undergo ter-
minal differentiation to plasma cells, which results in
a radical change of gene expression, as most B cell-spe-
cific genes includingPax5 are repressed, while a distinct
plasma cell-specific program is activated by Blimp1 and
Xbp1 (Shaffer et al., 2002; 2004). Here we have shown
that several Pax5-repressed genes are reexpressed in
plasma cells. Hence, the downregulation of Pax5 ex-
pression during terminal differentiation contributes to
the plasma cell transcription program by facilitating
the reactivation of lineage-promiscuous genes.
J-chain (Igj), Cd28, and Ccr2 are three of the Pax5-re-
pressed genes, which are reactivated in plasma cells.
While J-chain is known to be essential for the assembly
and secretion of pentameric IgM in plasma cells (Niles
et al., 1995), we have now discovered a B-lineage-intrin-
sic function of the CD28 and CCR2 receptors in plasma
cell differentiation by using a competitive bone marrow
reconstitution assay. Mice, which specifically lack
Cd28 or Ccr2 in the B lymphoid lineage, are able to
form normal germinal centers upon immunization with
NIP-Ova. However, the titers of NIP-specific IgG1 were
10-fold reduced in the serum of these mice compared
to controls, indicating that CD28 and CCR2 are impor-
tant for post-GC differentiation or function of plasma
cells. Future experiments will address whether CD28
and CCR2 signaling controls terminal differentiation,
cell survival, or efficient Ig secretion of plasma cells.
Whereas CD28 expression in T cells is required to pro-
mote the B-T cell collaboration leading to germinal cen-
ter formation (Shahinian et al., 1993; Ferguson et al.,
1996), we have now identified a B-lineage-intrinsic role
for CD28 in plasma cells.
Using conditional Pax5 inactivation in mature B cells,
we reinvestigated the role of Pax5 in controlling the ex-
pression of the GC-specific transcription factor Bcl6 and
the plasma cell regulators Xbp1 and Prdm1 (Blimp1).
This genetic approach did not reveal a role for Pax5 in
the regulation of Bcl6 and Xbp1 and thus contradicts
previous transient transfection data, which showed a
2-fold repression of a minimal Xbp1 promoter construct
by Pax5 overexpression in HeLa and B cells (Reimold
et al., 1996). Importantly however, the loss of Pax5 re-
sulted in activation of Blimp1 in mature B cells. Hence,
Pax5 appears to be involved in the repression of Blimp1
and the corresponding plasma cell transcription pro-
gram, similar to the role of Bcl6 in GC B cells (Shaffer
et al., 2000).Pax5-Dependent Gene Repression in B Cells
Is Essential for Blood Cell Homeostasis
Pax5 also represses the chemokine gene Ccl3 through-
out B cell development. CCL3 (MIP-1a) is not only
involved in the recruitment of leukocytes to sites of in-
flammation but is also expressed in multiple myeloma
cells, where it is responsible, as a potent osteoclasto-
genic factor, for bone destruction in tumor patients
(Oyajobi et al., 2003). To test whether the Pax5 repres-
sion function is essential for normal hematopoiesis, we
maintained Ccl3 expression from the Cd19 locus
throughout B cell development, which resulted in an os-
teopenic bone phenotype due to increased osteoclast
formation. The loss of trabecular bone in Cd19Ccl3 trans-
genic mice is likely to affect the function of HSCs in the
bone marrow, as specialized osteoblasts lining the tra-
becular bone surface act as key components of the
HSC niche (Suda et al., 2005). We conclude, therefore,
that normal hematopoiesis and bone formation depend
on the B cell-specific repression of Ccl3 by Pax5.
Experimental Procedures
Detailed methods can be found in Supplemental Data.
Mice
Wild-type and mutant mice were maintained on the C57BL/6 back-
ground.
Pro-B Cell Culture
Pro-B cells were cultured on g-irradiated ST2 cells in IL-7 containing
IMDM medium (Nutt et al., 1997).
cDNA Microarray Analysis
A pro-B cell microarray was created by spotting 10,000 cDNA inserts
from libraries that were generated by bidirectional subtraction of the
transcripts between Pax5+/+ andPax52/2 pro-B cells using the PCR-
Select cDNA Subtraction kit (Clontech). This microarray was hybrid-
ized with Cy3- and Cy5-labeled probes, scanned, and evaluated as
described (Schebesta et al., 2002).
Semiquantitative RT-PCR Analysis
cDNA was prepared from different hematopoietic cell types, and
semiquantitative PCR (Mikkola et al., 2002) was performed using
the primers listed in Table S2.
Conditional Pax5 Inactivation in Pro-B Cells
Cultured pro-B cells from CreED-30 Pax5F/F mice were treated with
1 mM 4-hydroxytamoxifen (OHT) and withdrawn at daily intervals
prior to semiquantitative RT-PCR analysis (Mikkola et al., 2002).
FACS Sorting and Analysis
Antibodies were obtained from PharMingen. The different cell types
were isolated by two consecutive rounds of FACS sorting (Figure S2)
as follows: LSK MPPs (Lin2IL-7Ra2Sca1hic-Kithi), CMP (Lin2Ly6C2
Sca12c-KithiCD31+), CLP (Lin2IL-7Ra+Sca1loc-Kitlo), pro-B (Lin2
CD19+c-Kit+), pre-B (Lin2CD19+CD25+IgM2), immature B cells
(Lin2CD19+IgM+IgD2), granulocytes (Mac1+Gr1+), and thymocytes
(Thy1.2+CD192). FACS reanalysis revealed a >99% purity of the dou-
ble-sorted cell populations (Figure S2).
Purification of Mature Pax5-Deficient B Cells
Lymph node cells were depleted of non-B cells with anti-CD33, CD4,
CD8a, CD11c, CD43, DX5, Gr1, Ly6C, Mac1, and Ter119 antibodies.
The mature B cells of theCd19-cre Pax5F/+ genotype were sorted as
Lin2CD252IgM+ B cells and Pax5-deficient mature B cells of the
Cd19-cre Pax5F/2 genotype as Lin2CD25+IgM+ B cells (Figure S3).
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280LPS Stimulation of Splenic B Cells
Sorted Lin2B220+CD19+ splenocytes of Vav-bcl2 mice were treated
for up to 9 days with 10 mg/ml LPS in IMDM medium containing 10%
fetal calf serum.
Isolation of Plasma Cells
IgHGFP/+ mice were immunized by intraperitoneal injection of 108
sheep red blood cells, and, 14 days later, plasma cells were sorted
from the bone marrow and spleen as Lin2GFPhiCD138hi cells (Fig-
ure S5).
Immunization and Determination of Ig Titers
Lethally irradiated Rag22/2 mice were transplanted with a 1:1 mix-
ture of 106 bone marrow cells from Vav-cre Pax5F/F mice and
Cd282/2, Ccr22/2, Ccl32/2, or wild-type mice. Six weeks later, the
reconstituted mice were immunized by subcutaneous injection of
50 mg NIP-Ovalbumin in complete Freund’s adjuvant. The titers of to-
tal and NIP-specific serum IgG1 were determined by ELISA 14 days
after immunization.
Generation of the Cd19Ccl3 Transgene
Mouse Ccl3 cDNA was inserted together with an IRES-hCd2t gene
into the mouse Cd19 BAC RP23-407K24 by standard BAC modifica-
tion (Schebesta et al., 2002). Transgenic mice were generated by in-
jection of supercoiled BAC DNA atw1 ng/ml into pronuclei of C57BL/
6xCBA F1 zygotes.
Histological Analysis and In Situ Hybridization
Long bones of E18.5 embryos were fixed, decalcified, and sectioned
prior to hematoxylin and eosin or TRAP staining. Decalcification was
omitted for van Kossa staining. Bone sections were in situ hybrid-
ized with a digoxygenin-labeled cathepsin K RNA probe. Cryosec-
tions of the spleen were stained with a FITC-anti-IgD antibody and
biotinylated PNA followed by detection with an alkaline phospha-
tase-coupled anti-FITC antibody (visualized with Fast Blue) and
with horseradish peroxidase-conjugated streptavidin (visualized
with DAB).
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, eight figures, and two tables and can be
found with this article online at http://www.immunity.com/cgi/
content/full/24/3/269/DC1/.
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